Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

Summary

This study aims to find out if taking specific dietary supplements (PEA and Scutellaria) along with therapeutic exercise can help reduce nerve pain and damage caused by chemotherapy. Many cancer patients experience nerve-related side effects from chemotherapy, which can significantly impact their quality of life. The study will observe patients who use these supplements and exercises to see if they can effectively manage and improve their nerve health and reduce pain.

Eligibility

Inclusion Criteria:

* Adults aged 18 years and older.
* Patients who have undergone chemotherapy treatment within the previous 6 months.
* Patients treated with PEA, Scutellaria, and standardized therapeutic exercise according to the EXCAP protocol from April 2025 to September 2025.
* Patients with a washout period from opioid-based analgesic therapy of at least 10 days or who are not receiving opioid-based analgesic therapy.
* Patients presenting with neuropathic pain (NRS ≥ 5).
* Patients able to provide written informed consent.

Exclusion Criteria:

* Patients younger than 18 years.
* Patients with hypersensitivity to PEA or any of the excipients listed in the Summary of Product Characteristics (SPC).
* Patients with diabetic pathology.
* Patients with severe hepatic impairment.
* Patients with severe disabilities that compromise the execution of therapeutic exercise.

Conditions3

Browse More Trials